SSY GROUP (02005): Three drugs receive drug production registration approval and are all deemed to have passed consistency evaluation.

SSY GROUP (02005) announced that the Group has obtained drug production registration approvals from China's National Medical Products Administration for the following three products, all of which are Class 4 chemical drugs and are deemed to have passed consistency evaluation. 1. Compound Tropicamide Eye Drops (0.4ml): This product is mainly used for mydriasis and cycloplegia for diagnostic and therapeutic purposes. Compound Tropicamide Eye Drops is a commonly used preparation for ophthalmic mydriasis and refractive examination, featuring rapid onset and short duration of action, with clear clinical necessity. This product adopts 0.4ml single-use single-dose packaging and is preservative-free, with a single optometry dose matching usage and less drug solution waste, making it more suitable for pediatric refractive screening scenarios and enriching the Group's ophthalmic medication product line. 2. Tofacitinib Citrate Extended-Release Tablets (11mg): This product is mainly indicated for adult patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Tofacitinib is an oral small-molecule JAK inhibitor, with overall clinical efficacy comparable to TNF- inhibitor biologic monoclonal antibodies. Compared with biologics requiring regular injections, this product's extended-release formulation enables once-daily oral administration, greatly improving convenience of use and offering significant advantages in long-term medication compliance for patients. The Group has supporting self-produced API capacity, forming an integrated API plus formulation layout with controllable costs and a stable supply chain. The product has prominent differentiated advantages and is highly suitable for rheumatology and immunology chronic disease management scenarios. The Group can focus on laying out dual-channel and out-of-hospital retail market channels to achieve long-term steady penetration. 3. Sacubitril Valsartan Sodium Tablets (200mg): This product is mainly used for adult patients with chronic heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and heart failure hospitalization. Sacubitril Valsartan Sodium Tablets is a first-line medication recommended by guidelines for heart failure and hypertension. This product has both blood pressure-lowering and cardiovascular target organ protection effects, with clear clinical benefits, further enriching and improving the Group's product portfolio in the cardiovascular and cerebrovascular chronic disease field.